Phaseline

Targets › ACLY

ACLY (ATP-citrate synthase): drug programs, companies and trials

1 program from 1 company in 5 trials: 2 Phase 4, 2 Phase 2, 1 Phase 3; Cardiovascular, Genitourinary, Immunology.

Catalyzes the cleavage of citrate into oxaloacetate and acetyl-CoA, the latter serving as common substrate in multiple biochemical reactions in protein, carbohydrate and lipid metabolism. (UniProt, P53396)

Open in Phaseline: the race on ACLY, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gan & Lee Pharmaceuticals.Bempedoic Acid
ATP-citrate synthase inhibitor
ACLYPhase 3Primary Hyperlipidemia; Acute Coronary Syndromes; Rheumatoid Arthritis (RA); Dyslipidemias …–

Conditions

Primary Hyperlipidemia (1) Acute Coronary Syndromes (1) Rheumatoid Arthritis (RA) (1) Dyslipidemias (1) ADPKD (Autosomal Dominant Polycystic Kidney Disease) (1)

Modalities

small molecule (1)

Companies

Gan & Lee Pharmaceuticals. (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.